What is Astellas Pharma?
Astellas Pharma is a pharmaceutical company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Pharmaceutical company
- Headquarters
- Tokyo, Japan
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; TSE: 4503
What is Astellas Pharma?
Astellas Pharma is a pharmaceutical company company headquartered in Tokyo, Japan. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Astellas Pharma is a pharmaceutical company company headquartered in Tokyo, Japan. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Astellas Pharma should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Astellas Pharma offer?
Astellas Pharma's profile centers on Oncology, Urology, Immunology, Gene therapies.
- Oncology· Pharmaceutical company
- Urology· Pharmaceutical company
- Immunology· Pharmaceutical company
- Gene therapies· Pharmaceutical company
- Clinical development· Pharmaceutical company
- Global commercialization· Pharmaceutical company
How does Astellas Pharma make money?
Astellas Pharma makes money through commercial activity tied to pharmaceutical company.
Astellas Pharma monetizes through the model common to pharmaceutical company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Astellas Pharma?
Astellas Pharma's named executives should be verified on the official leadership or investor-relations page before outreach.
- Astellas Pharma executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Astellas Pharma finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Astellas Pharma operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Astellas Pharma's leadership?
Astellas Pharma should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.astellas.com- Astellas Pharma investor relationsInvestor relations / corporate contactcontact via https://www.astellas.com
- Astellas Pharma media relationsMedia or communications contact routecontact via https://www.astellas.com
How is Astellas Pharma funded?
Astellas Pharma's current status is Public company; TSE: 4503.
Astellas Pharma's capital profile is best understood through its current public-company status: Public company; TSE: 4503. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Astellas Pharma get here?
Astellas Pharma's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingAstellas Pharma is foundedThe company begins building in pharmaceutical company.
- Scale-upCommercial footprint expandsAstellas Pharma broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; TSE: 4503Public-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Astellas Pharma's competitors?
Astellas Pharma competes with larger incumbents and focused specialists in pharmaceutical company.
Astellas Pharma — frequently asked questions
